Compare DexCom, Inc. (DXCM) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs VanEck Vietnam ETF — how do they compare? DexCom, Inc. trades at $77.2 (market cap $28.06B), while VanEck Vietnam ETF trades at $17.46. The key difference: DexCom, Inc. is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | VNM | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Sector/Thematic |
52-Week High | $89.53 | $19.80 |
52-Week Low | $54.84 | $15.35 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
VNM trades at $17.485, down 1.05% today, with a bearish technical signal driven by moving averages. The RSI-6 at 18.54 suggests oversold conditions, while support and resistance cluster tightly around $17. Financial ratios are unavailable, limiting fundamental clarity. Recent news highlights Vietnam ETF underperformance and external pressures like heatwave strain on the national grid.
The outlook remains cautious due to technical weakness and emerging market volatility. Investment opportunities hinge on Vietnam's economic resilience and potential foreign inflows from FTSE Russell's reclassification. Key risks include geopolitical tensions, power grid instability, and broader EM underperformance versus global markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
